Sun Yat-sen University
1,871
385
470
414
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
3.5%
66 terminated/withdrawn out of 1871 trials
86.3%
-0.3% vs industry average
19%
359 trials in Phase 3/4
5%
21 of 414 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1871)
Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease
Role: lead
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
Role: lead
Accelerated Temporal Interference Stimulation on Bilateral Subthalamic Nucleus for Parkinson's Disease and Secondary Parkinson's Syndrome
Role: collaborator
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Role: lead
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Role: lead
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Role: lead
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Role: lead
Postoperative Anxiety and Depression Among Chinese Elderly Patients
Role: collaborator
Theory-Based Parenting Intervention for Preschool Children's Health Behaviors
Role: lead
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Role: lead
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Role: lead
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
Role: lead
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Role: lead
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
Role: lead
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Role: lead
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
Role: lead
Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
Role: lead
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Role: lead
Full-wrap Suspension Versus Double-Strap Suspension for Reducing the Incidence of Soft Palate Injury: A Prospective Multi-center Randomized Controlled Trial
Role: lead
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Role: lead